Christian Marsolais

Company: Theratechnologies Inc.

Job title: Senior Vice-President and Chief Medical Officer

Seminars:

Targeting Sortilin (SORT1) to Unlock the Potential of Peptide Drug Conjugates (PDCs) in Oncology: Rapid Internalization Within Minutes with Unique Multimodal MOA and Safety Profile 10:00 am

Understand the rationale for targeting the SORT1 receptor in cancer Discuss the unique toxicity profile of sudocetaxel zendusortide (TH1902), the lead PDC from Theratechnologies’ SORT1+ Technology™ platform, that differs substantially from the safety profile of taxanes, due to the multimodal MOA of the conjugate and the low levels of free circulating docetaxel Discuss how this…Read more

day: Conference Day 1